NCCN 2014 Conference

Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options

Wayne Kuznar

April 2014, Vol 5, No 3 - NCCN 2014 Conference

Hollywood, FL—The updated National Comprehensive Cancer Network (NCCN) guidelines for the management of melanoma now include the BRAF inhibitor dabrafenib (Tafinlar) as a Category 1 recommendation for the primary treatment of patients with metastatic melanoma and BRAF mutation, as well as the use of the mitogen-activated protein kinase (MEK) inhibitor trametinib (Mekinist) for the treatment of patients with melanoma and BRAF mutation. These 2 drugs, which received US Food and Drug Administration (FDA) approval last year, are now added to the NCCN targeted therapies for the treatment of patients with advanced or metastatic melanoma. [ Read More ]